Craneware Plc (CRW) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Craneware Plc £11.20, price £10.18, upside +10.0%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Craneware Plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range £9.96 – £25.50 · fair‑value band £8.40 – £14.00 · the £10.18 price screens below the £11.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 4, 2026.
Follow Craneware in your weekly email
Every Wednesday you see whether Craneware is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States.
Show more
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. It provides solutions, such as Trisus Pricing Analyzer and Transparency, a solution that optimizes and automates the price modeling process; Trisus Chargemaster, an automated chargemaster management solution; InSight Medical Necessity, a solution that offers medical necessity requirements; Trisus Claims Informatics, a retrospective charge capture analytical application; Trisus Supply, a solution that improves supplies reimbursement; and InSight Audit, an audit solution for government and commercial payors. The company also offers Trisus Decision Support; Trisus Labor Productivity, which enables healthcare providers to manage, analyze, and plan the deployment of workforce; Trisus Medication Analytic solutions that prioritize, diagnose, and resolve issues in medication systems; and Trisus Supplies Assistant solutions which supplies charged data. In addition, it provides Sentrex, a SaaS-based solution that helps covered entities expand medication access; Sentinel, that tracks all drug activity; Referral Verification System; and Central Pharmacy Distribution, a centralized purchasing application. Further, the company offers professional, pharmacy professional, and appeal services. Additionally, the company provides The Academy, an interactive learning center for user training; Trisus Pricing Integrity Suite; Trisus Business of Pharmacy Suite, which offers solutions centered on each link in the medication revenue cycle; Trisus Value-based Margin and Productivity Suite; and Trisus Data Integrity Suite, which creates a proactive workflow that aligns data between operating units, the supply chain and revenue cycle. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
Stock analysis
Craneware Plc (CRW) currently trades at £10.18, while our model-based Fair Value estimate is £11.20, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £14.46 per share, and 13 of the 26 models we run sit above the £10.18 price.
Bear case: the Dividend Discount group reads lowest at £4.45, and 13 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: £8.40 (bear) to £14.00 (bull), the price of £10.18 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Craneware Plc reported revenue of $206M in FY2026 versus $166M in FY2022, a compound +5.7%/yr. Reported net income was $19.8M in FY2026, compounding +20.4%/yr from FY2022.
Key figures
Market cap 354M GBX · P/E ratio 24.2 · P/S ratio 2.32 · EPS (TTM) £0.4200 · Dividend yield 3.3% · Net margin 9.6% · Return on equity 6.0% · Return on assets (EBIT) 4.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 57% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 10%, CRW screens cheaper than that median.
Fair Value models
Bear £8.40Fair Value £11.20Bull £14.00
Price £10.18 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 3 months old). Earnings retained since then (£0.0224 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.3%
Start year 2021 (pandemic). Over 10 years: +15.3% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+15.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.8%
Dividend (yield on the price)3.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.3.7% vs 3.9%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 13%
2026 sits 72% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2021 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about 0.0% a year for the price and −2.0% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 116 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+10.0% · Above median
Profitability
Return on equity (TTM)6.0% · Above median
Return on assets3.1% · Above median
Net margin (TTM)9.6% · Above median
Operating margin (TTM)13.2% · Above median
Growth and dividend
Revenue growth−5.1% · Bottom 25%
Dividend yield (TTM)3.3% · Above median
Balance sheet
Debt / equity0.09× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (TTM)24.2× · Cheaper than median
P/B1.46× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Craneware Plc Fair Value". https://www.fairvalue-calculator.com/stock/CRW
Frequently asked questions
Is Craneware Plc (CRW) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of £11.20 versus a price of £10.18, about +10% upside (undervalued).
What is the fair value of CRW?
Our model-based fair value for Craneware Plc is £11.20 (as of Oct 4, 2026), built from audited fundamentals. The current price: £10.18.
What is the quality score of CRW?
Craneware Plc has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Craneware Plc (CRW)?
Our model-based price target is the fair value of £11.20 (as of Oct 4, 2026) from 26 valuation models. Cautious scenario £8.40, optimistic scenario £14.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Craneware Plc stock forecast for 2026?
Our models put fair value at £11.20, about +10% upside versus a price of £10.18 (undervalued). Cautious scenario £8.40, optimistic scenario £14.00. The calculation is refreshed regularly with new filings.
What is the revenue of Craneware Plc (CRW)?
Craneware Plc reported trailing-twelve-month revenue of about $206M (latest available figure, as of Oct 4, 2026).
Does Craneware Plc pay a dividend?
Craneware Plc currently shows a dividend yield of about 3.29% relative to its recent price (as of Oct 4, 2026).
What growth is priced into Craneware Plc (CRW)?
For today's price to be fair in a discounted-cash-flow model, Craneware Plc would have to grow free cash flow by +2.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.3 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of CRW use?
Our models discount Craneware Plc at 11.8 %: a base by market capitalisation (small), country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Craneware Plc that is +2.4 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Craneware Plc (CRW) delivered so far?
Over the past 5 years revenue at Craneware Plc grew +22.3 % a year. The price currently implies +2.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Craneware Plc (CRW) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Craneware Plc (+2.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Craneware Plc (CRW)?
The free-cash-flow yield on the price is 9.02 %: that much free cash flow Craneware Plc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Craneware Plc (CRW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Craneware Plc it is £11.20 per share (as of Oct 4, 2026), against a price of £10.18. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Craneware Plc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, CRW trades below its calculated fair value: price £10.18, fair value £11.20, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRW?
No. The price is what the market pays today (£10.18); the fair value is what the company's own numbers justify (£11.20). For Craneware Plc the two are £1.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Craneware Plc worth?
The market values Craneware Plc at about 354M GBX (market capitalisation, as of Oct 4, 2026). Per share that is £10.18; our models calculate a fair value of £11.20 per share.
What do the bullish and bearish scenarios say about CRW?
Our models span a range for Craneware Plc: cautious scenario £8.40, base £11.20, optimistic £14.00 per share (as of Oct 4, 2026, price £10.18). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CRW?
Craneware Plc trades at a price-to-earnings ratio of 24.2 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £11.20 is built from several models across several years. Other multiples: P/B 1.5, P/S 2.3, EV/EBITDA 11.3.
How solid is the balance sheet of Craneware Plc (CRW)?
Balance-sheet figures for Craneware Plc (as of Oct 4, 2026): return on equity 6.0%, debt of 0.09 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is CRW from its 52-week high?
Craneware Plc trades at £10.18, about 57% below its 52-week high of £23.44 and 2% above the low of £9.96 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £11.20 is for.
Which stocks are comparable to Craneware Plc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Craneware Plc stock attractive at the current price?
The data as of Oct 4, 2026: price £10.18, calculated fair value £11.20 (+10%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRW calculated?
We run Craneware Plc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £11.20, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Craneware Plc currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Craneware Plc (CRW)?
The closing price on Oct 2, 2026 was £10.18. Our model-based fair value is £11.20, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Craneware Plc right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Craneware Plc (CRW) come from?
Earnings per share at Craneware Plc grew +1.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +13.2 %, EBIT margin −8.9 %, tax rate +0.1 %, residual (interest, one-offs) −1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Craneware Plc
How large is the market capitalisation of Craneware Plc (CRW)?
The market capitalisation of Craneware Plc is 354M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Craneware Plc (CRW)?
The price-to-sales ratio of Craneware Plc is 2.32 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Craneware Plc (CRW)?
Earnings per share at Craneware Plc are £0.4200 (price ÷ EPS = P/E 24.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Craneware Plc (CRW)?
The dividend yield of Craneware Plc is 3.3% (payout 79.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Craneware Plc (CRW)?
The net margin of Craneware Plc is 9.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Craneware Plc (CRW)?
The return on equity (ROE) of Craneware Plc is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Craneware Plc (CRW)?
On an EBIT basis the return on assets of Craneware Plc is 4.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Craneware Plc (CRW)?
The operating margin of Craneware Plc is 13.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Craneware Plc (CRW)?
Revenue at Craneware Plc is growing −5.1% versus a year earlier (3y avg +5.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Craneware Plc (CRW)?
Earnings per share at Craneware Plc are growing −19.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Craneware Plc (CRW) hold?
Craneware Plc holds more cash than debt, $8.3M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Craneware Plc in the live analysis
One click puts Craneware Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
